SCHEMBL4107284

SCHEMBL4107284

CCN(CC)CCN(CCNC(=O)Nc1cccc(C(F)(F)F)c1)C(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 3/20 0.59
▸ TP53 P04637 2/20 0.53
▸ MAPT P10636 5/20 0.51
▸ HTT P42858 5/20 0.51
▸ SMN1; SMN2 Q16637 5/20 0.51
▸ LMNA P02545 5/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ XBP1 P17861 2/20 0.51
▸ GAA P10253 1/20 0.51
▸ PAX8 Q06710 1/20 0.51
▸ MEN1 O00255 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.48
▸ GOT1 P17174 1/20 0.47
▸ ALOX15 P16050 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ UBE2M P61081 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4116381 0.96 MCHR1 (0.58) MCHR1TP53MAPTHTTSMN1; SMN2
SCHEMBL4115328 0.87 MCHR1 (0.61) MCHR1MAPTHTTSMN1; SMN2GAA
SCHEMBL4118376 0.87 MCHR1 (0.66) MCHR1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4129057 0.86 KMT2A (0.46) MCHR1MAPTSMN1; SMN2LMNAMEN1
SCHEMBL11797984 0.85 MCHR1 (0.61) MCHR1TP53MAPTHTTSMN1; SMN2
SCHEMBL4119938 0.85 TP53 (0.54) MCHR1TP53MAPTHTTSMN1; SMN2
SCHEMBL4115322 0.85 TP53 (0.56) MCHR1TP53MAPTHTTSMN1; SMN2
SCHEMBL4107138 0.85 CNR1 (0.55) MCHR1TP53MAPTHTTSMN1; SMN2
SCHEMBL4119645 0.82 MCHR1 (0.60) MCHR1MAPTHTTSMN1; SMN2GAA
SCHEMBL4107405 0.82 MCHR1 (0.60) MCHR1MAPTHTTSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118330-A1 Diurea derivatives ACTIVE BIOTECH AB (SE) 2009-05-07 — — US claimed
EP-1711175-A1 DIUREA DERIVATIVES Active Biotech AB (SE) 2006-10-18 — — EP claimed
WO-2005074919-A1 DIUREA DERIVATIVES ACTIVE BIOTECH AB (SE) 2005-08-18 — — WO claimed
US-20090118330-A1 Diurea derivatives ACTIVE BIOTECH AB (SE) 2009-05-07 — — US disclosed
EP-1711175-A1 DIUREA DERIVATIVES Active Biotech AB (SE) 2006-10-18 — — EP disclosed
WO-2005074919-A1 DIUREA DERIVATIVES ACTIVE BIOTECH AB (SE) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118330-A1 Diurea derivatives IL2, CASP2, MAVS MCHR1 4128/4885TP53 366/4885MAPT 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback